Glen Reid

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/701141/publications.pdf

Version: 2024-02-01

102 papers	7,392 citations	71102 41 h-index	54911 84 g-index
103 all docs	103 docs citations	103 times ranked	9959 citing authors

#	Article	IF	Citations
1	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncology, The, 2017, 18, 1386-1396.	10.7	508
2	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9244-9249.	7.1	478
3	Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PLoS ONE, 2011, 6, e24145.	2.5	442
4	Circulating microRNAs: Association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology, 2011, 80, 193-208.	4.4	421
5	Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics, 2002, 1, 417-25.	4.1	371
6	Characterization of the Transport of Nucleoside Analog Drugs by the Human Multidrug Resistance Proteins MRP4 and MRP5. Molecular Pharmacology, 2003, 63, 1094-1103.	2.3	346
7	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochemical Journal, 2003, 371, 361-367.	3.7	291
8	The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics, 2013, 4, 94.	2.3	266
9	Characterization of the MRP4- and MRP5-mediated Transport of Cyclic Nucleotides from Intact Cells. Journal of Biological Chemistry, 2003, 278, 17664-17671.	3.4	233
10	Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3). Journal of Biological Chemistry, 2001, 276, 46400-46407.	3.4	227
11	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Annals of Oncology, 2013, 24, 3128-3135.	1.2	221
12	Interactions between Hepatic Mrp4 and Sult2a as Revealed by the Constitutive Androstane Receptor and Mrp4 Knockout Mice. Journal of Biological Chemistry, 2004, 279, 22250-22257.	3.4	211
13	Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP) Tj ETQq1 1 0.784314 rgBT /Overloc	3.4	177
14	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics, 2016, 8, 1079-1085.	2.1	176
15	Thiopurine Metabolism and Identification of the Thiopurine Metabolites Transported by MRP4 and MRP5 Overexpressed in Human Embryonic Kidney Cells. Molecular Pharmacology, 2002, 62, 1321-1331.	2.3	174
16	Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophysical Reviews, 2018, 10, 69-86.	3.2	146
17	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant PleuralÂMesothelioma. Journal of Thoracic Oncology, 2017, 12, 1421-1433.	1.1	121
18	Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2012, 7, 1184-1191.	1.1	115

#	Article	IF	Citations
19	The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates. Cancer Research, 2005, 65, 4425-4430.	0.9	114
20	Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. Journal of Clinical Pathology, 2013, 66, 847-853.	2.0	104
21	YB-1, the E2F Pathway, and Regulation of Tumor Cell Growth. Journal of the National Cancer Institute, 2012, 104, 133-146.	6.3	102
22	The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB Journal, 2007, 21, 3592-3605.	0.5	95
23	Cloning of a Human Renal pâ€“Aminohippurate Transporter, hROAT1. Kidney and Blood Pressure Research, 1998, 21, 233-237.	2.0	86
24	Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 2011, 6, 1923-1929.	1.1	82
25	Protein Kinase C Activation Downregulates Human Organic Anion Transporter 1-Mediated Transport through Carrier Internalization. Journal of the American Society of Nephrology: JASN, 2003, 14, 1959-1968.	6.1	79
26	microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget, 2015, 6, 36675-36688.	1.8	79
27	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 2015, 6, 23480-23495.	1.8	76
28	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 2015, 113, 963-969.	6.4	68
29	MiRâ€Score: A novel 6â€microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology, 2015, 9, 715-726.	4.6	67
30	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1467-1469.	5.6	66
31	Cell-free microRNAs: potential biomarkers in need of standardized reporting. Frontiers in Genetics, 2013, 4, 56.	2.3	60
32	Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Advanced Drug Delivery Reviews, 2002, 54, 1333-1342.	13.7	54
33	Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Journal of Clinical Pathology, 2013, 66, 854-861.	2.0	54
34	Genomic Structure and in Vivo Expression of the Human Organic Anion Transporter 1 (hOAT1) Gene. Biochemical and Biophysical Research Communications, 2000, 275, 623-630.	2.1	51
35	The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Research, 2004, 62, 1-7.	4.1	51
36	Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemotherapy and Pharmacology, 2011, 68, 603-610.	2.3	48

#	Article	IF	Citations
37	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2018, 7, 153.	2.4	47
38	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. Npj Systems Biology and Applications, 2018, 4, 20.	3.0	47
39	KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. Molecular Cancer, 2016, 15, 44.	19.2	46
40	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 2014, 110, 510-519.	6.4	45
41	Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. Molecular Cancer Research, 2015, 13, 1106-1118.	3.4	44
42	Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metabolism Reviews, 2010, 42, 590-611.	3.6	43
43	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 258-272.	1.1	40
44	MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets. Journal of Thoracic Disease, 2015, 7, 1031-40.	1.4	39
45	The Î”133p53Î² isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. Cell Death and Disease, 2019, 10, 631.	6.3	36
46	Exploring Mechanisms of MicroRNA Downregulation in Cancer. MicroRNA (Shariqah, United Arab) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.2	36
47	Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS ONE, 2013, 8, e70940.	2.5	33
48	FGF2 and EGF induce epithelialâ€“mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis, 2018, 39, 534-545.	2.8	32
49	Malignant mesothelioma. Internal Medicine Journal, 2010, 40, 742-750.	0.8	31
50	ZIC1 Is Silenced and Has Tumor Suppressor Function in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2013, 8, 1317-1328.	1.1	30
51	Mutational Analysis of Hedgehog Signaling Pathway Genes in Human Malignant Mesothelioma. PLoS ONE, 2013, 8, e66685.	2.5	29
52	A link between the fibroblast growth factor axis and the miRâ€16 family reveals potential new treatment combinations in mesothelioma. Molecular Oncology, 2018, 12, 58-73.	4.6	27
53	Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future. Frontiers in Oncology, 2020, 10, 105.	2.8	27
54	Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology, 2011, 43, 128-132.	0.6	26

#	Article	IF	Citations
55	Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. Frontiers in Cell and Developmental Biology, 2019, 7, 221.	3.7	26
56	Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins Î±vÎ²3 and Î±vÎ²5. PLoS ONE, 2014, 9, e90374.	2.5	26
57	Asbestos-related cancers: the â€˜Hidden Killerâ€™ remains a global threat. Expert Review of Anticancer Therapy, 2020, 20, 271-278.	2.4	25
58	Inflammation in malignant mesothelioma - friend or foe?. Annals of Cardiothoracic Surgery, 2012, 1, 516-22.	1.7	24
59	Blockade of Aquaporin 1 Inhibits Proliferation, Motility, and Metastatic Potential of MesotheliomaIn Vitrobut not in anIn VivoModel. Disease Markers, 2015, 2015, 1-9.	1.3	23
60	Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. Journal of Rnai and Gene Silencing, 2009, 5, 321-30.	1.2	22
61	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma â€“ A multi-institutional study. European Journal of Cancer, 2016, 63, 64-73.	2.8	21
62	A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5â€² RACE and a molecular beacon probe. Nucleic Acids Research, 2010, 38, e19-e19.	14.5	20
63	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 2016, 114, 524-531.	6.4	20
64	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. Critical Reviews in Oncology/Hematology, 2020, 150, 102949.	4.4	20
65	Exploiting microRNAs As Cancer Therapeutics. Targeted Oncology, 2017, 12, 163-178.	3.6	18
66	Biomarkers in malignant pleural mesothelioma: current status and future directions. Journal of Thoracic Disease, 2018, 10, S1003-S1007.	1.4	17
67	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer, 2019, 130, 35-41.	2.0	17
68	Molecular biomarkers in malignant mesothelioma: state of the art. Pathology, 2011, 43, 201-212.	0.6	16
69	SFRPTumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. Disease Markers, 2017, 2017, 1-10.	1.3	16
70	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy. Cancer Research, 2015, 75, 3976-3976.	0.9	15
71	Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Oncotarget, 2019, 10, 4125-4138.	1.8	13
72	Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. Frontiers in Genetics, 2017, 8, 70.	2.3	12

#	Article	IF	Citations
73	The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Research Notes, 2011, 4, 148.	1.4	11
74	BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PLoS ONE, 2018, 13, e0203003.	2.5	10
75	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology, 2019, 10, 89.	3.5	10
76	The Potency of siRNA-Mediated Growth Inhibition Following Silencing of Essential Genes Is Dependent on siRNA Design and Varies With Target Sequence. Oligonucleotides, 2009, 19, 317-328.	2.7	9
77	The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. BMC Research Notes, 2017, 10, 600.	1.4	9
78	Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress. Redox Biology, 2020, 28, 101374.	9.0	9
79	YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms. Cancers, 2020, 12, 2285.	3.7	8
80	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. JTO Clinical and Research Reports, 2020, 1, 100075.	1.1	8
81	Response to â€œAn innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)â€• Translational Lung Cancer Research, 2018, 7, S60-S61.	2.8	7
82	THE MULTIDRUG RESISTANCE PROTEINS 3â€“7. , 2003, , 445-458.		6
83	MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. Genomics Data, 2016, 9, 44-49.	1.3	5
84	Asbestos and Zeolites: from A to Z via a Common Ion. Chemical Research in Toxicology, 2021, 34, 936-951.	3.3	5
85	Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. , 2019, 2, 1193-1206.		5
86	Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma. FASEB BioAdvances, 2019, 1, 550-560.	2.4	4
87	P1.05-021 circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S626-S627.	1.1	3
88	Editorial: Emerging Therapies for Malignant Mesothelioma. Frontiers in Oncology, 2020, 10, 939.	2.8	3
89	Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?. Annals of Cardiothoracic Surgery, 2012, 1, 481-6.	1.7	3
90	Differential Expression of BARD1 Isoforms in Melanoma. Genes, 2021, 12, 320.	2.4	2

#	Article	IF	Citations
91	MTE29.02 Advances in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S182-S184.	1.1	1
92	OA02.05 Expression of miR-223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumor Microenvironment. Journal of Thoracic Oncology, 2017, 12, S248.	1.1	1
93	Asbestos and the Pathophysiology of Mesothelioma. , 2019, , 19-33.		1
94	Covalent binding of molecules to plasma immersion ion implantationâ€activated microparticles for delivery into cells. Engineering Reports, 2020, 2, e12087.	1.7	1
95	Erratum by the Publisher â€“ Announcement. Kidney and Blood Pressure Research, 1998, 21, 459-459.	2.0	0
96	Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression?. Chest, 2013, 144, 1971.	0.8	0
97	Welcome Message from Conference Co-Convenors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 1-1.	1.1	0
98	MicroRNAs and Cancer. , 2015, , 67-90.		0
99	Using a multidisciplinary approach to combat the burden of asbestosâ€related disease. Medical Journal of Australia, 2016, 204, 52-52.	1.7	0
100	P3.03-007 miR-137 Acts as a Tumor Suppressor viaÂthe Down-Regulation of YB-1 in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S1347-S1348.	1.1	0
101	ED13.02 Tissue-Based Biomarkers. Journal of Thoracic Oncology, 2017, 12, S57-S58.	1.1	0
102	OA02.03 Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study. Journal of Thoracic Oncology, 2017, 12, S247-S248.	1.1	0